Drugs / Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00635830 | Mar → Apr 2008 | human papilloma virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 34 trials · 1 met primary | ||||||
| Phase 3 | NCT05383625 | Sep 2020 → Oct 2021 | common wart | Zagazig University | Completed | No outcome recorded |
| Phase 3 | NCT02382900 | Feb → Oct 2015 | human papilloma virus infection | Universidad Nacional Autonoma de Mexico | Unknown | No outcome recorded |
| Phase 3 | NCT00834106 | Dec 2008 → May 2012 | human papilloma virus infection | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 3 | NCT00380367 | May 2007 → Feb 2008 | human papilloma virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT00551187 Background | Oct 2007 → May 2009 | cervical cancer, human papilloma virus infection, vaginal cancer, vulva cancer | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00520598 Comparator | Oct 2007 → May 2011 | anogenital human papillomavirus infection, cervical cancer, vaginal cancer, vulva cancer | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine | “0.5 ml injection of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine as 3 dose regimen at Day 1, Month 2 and Month 6.” NCT00520598 ↗6“Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine 0.5 ml injection in 3 dose regimen for 6 month treatment period.” NCT00551187 ↗ |
| Known as | qHPV | “The quadrivalent human papillomavirus (qHPV; HPV6/11/16/18) and 9-valent HPV (9vHPV; HPV6/11/16/18/31/33/45/52/58) vaccines have demonstrated efficacy, immunogenicity, and...” PMID 35997582 ↗ Aug 2022 |
| Known as | Quadrivalent HPV vaccine | “Quadrivalent HPV vaccine (6, 11, 16, 18) given intramuscularly on Day 1, Month 2, and Month 6.” NCT00380367 ↗ |
| Modality | Vaccine | “Quadrivalent HPV Vaccine is composed of L1 virus-like particles (VLPs) from HPV types 6, 11, 16, and 18.” NCT00380367 ↗ |
| Route | Intramuscular | “Quadrivalent HPV vaccine (6, 11, 16, 18) given intramuscularly on Day 1, Month 2, and Month 6.” NCT00380367 ↗ |